Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
5.06
+0.07 (1.40%)
At close: Apr 28, 2026, 4:00 PM EDT
5.16
+0.10 (1.95%)
After-hours: Apr 28, 2026, 5:44 PM EDT
Protara Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Protara Therapeutics stock have an average target of 23.6, with a low estimate of 21 and a high estimate of 27. The average target predicts an increase of 366.40% from the current stock price of 5.06.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 4, 2026.
Analyst Ratings
The average analyst rating for Protara Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 4 | 4 | 3 |
| Buy | 2 | 2 | 3 | 3 | 4 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Initiates $27 | Buy | Initiates | $27 | +433.60% | Mar 4, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +354.55% | Feb 10, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $24 | Buy | Initiates | $24 | +374.31% | Jan 7, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +354.55% | Dec 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +354.55% | Nov 19, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.43M
EPS This Year
-1.55
from -1.34
EPS Next Year
-1.65
from -1.55
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 7.4M | ||||||
| Avg | n/a | 1.4M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.07 | -1.19 | ||||||
| Avg | -1.55 | -1.65 | ||||||
| Low | -1.81 | -1.97 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.